HER2 Support Group Forums - View Single Post

Hopeful · 02-05-2007, 01:32 PM

Rinaina,

I was able to find some of the information I mentioned.

1. Here is a link to an article about the truncated form of Her2: http://clincancerres.aacrjournals.or...t/full/8/2/347. The authors state, "the full length receptor p185HER-2 undergoes a metalloprotease-dependent clevage producing a membrane-associated fragment (p95HER-2)in cultured cancer breast cells." They state "We report here that, in contrast to the full length receptor, p95HER-2 is more frequently expressed in lymph node metastatic tissue (45.7%) than in primary tumors (26.7%). If the truncated kinase p95 has a role in metastasis, as one study suggests, its presence may identify patients that are unlikely to respond to trastuzumab. Dmall molecule tyrosine kinase inhibitors may prove to be effective against p95-positive breast cancer."

2. Here is a link to the press release about the study on cymc: http://www.nsabp.pitt.edu/cMYC_Press_Release_121505.pdf. I have also read some comments about this relationship in the Breast Cancer Update materials - the links are generally posted in Articles of Interest.

3. Here is a link to an article about PTEN and Herceptin sensitivity: http://www.nature.com/bjc/journal/v9.../6602926a.html

I hope this helps.

Hopeful

02-05-2007, 01:32 PM	#5
Hopeful Senior Member Join Date: Aug 2006 Posts: 3,380	Rinaina, I was able to find some of the information I mentioned. 1. Here is a link to an article about the truncated form of Her2: http://clincancerres.aacrjournals.or...t/full/8/2/347. The authors state, "the full length receptor p185HER-2 undergoes a metalloprotease-dependent clevage producing a membrane-associated fragment (p95HER-2)in cultured cancer breast cells." They state "We report here that, in contrast to the full length receptor, p95HER-2 is more frequently expressed in lymph node metastatic tissue (45.7%) than in primary tumors (26.7%). If the truncated kinase p95 has a role in metastasis, as one study suggests, its presence may identify patients that are unlikely to respond to trastuzumab. Dmall molecule tyrosine kinase inhibitors may prove to be effective against p95-positive breast cancer." 2. Here is a link to the press release about the study on cymc: http://www.nsabp.pitt.edu/cMYC_Press_Release_121505.pdf. I have also read some comments about this relationship in the Breast Cancer Update materials - the links are generally posted in Articles of Interest. 3. Here is a link to an article about PTEN and Herceptin sensitivity: http://www.nature.com/bjc/journal/v9.../6602926a.html I hope this helps. Hopeful